JP2022515480A - 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体 - Google Patents

掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体 Download PDF

Info

Publication number
JP2022515480A
JP2022515480A JP2021537716A JP2021537716A JP2022515480A JP 2022515480 A JP2022515480 A JP 2022515480A JP 2021537716 A JP2021537716 A JP 2021537716A JP 2021537716 A JP2021537716 A JP 2021537716A JP 2022515480 A JP2022515480 A JP 2022515480A
Authority
JP
Japan
Prior art keywords
week
seq
amino acid
acid sequence
ppp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021537716A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022515480A5 (enExample
Inventor
トーマ，クリスティアン
バウム，パトリック
ラマー，ジャニン
パドゥラ，スティーヴン・ジョン
Original Assignee
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング filed Critical ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング
Publication of JP2022515480A publication Critical patent/JP2022515480A/ja
Publication of JP2022515480A5 publication Critical patent/JP2022515480A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
JP2021537716A 2018-12-27 2019-12-20 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体 Pending JP2022515480A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862785316P 2018-12-27 2018-12-27
US62/785,316 2018-12-27
US201962815431P 2019-03-08 2019-03-08
US62/815,431 2019-03-08
US201962891464P 2019-08-26 2019-08-26
US62/891,464 2019-08-26
PCT/EP2019/086521 WO2020136101A1 (en) 2018-12-27 2019-12-20 Anti-il-36r antibodies for treatment of palmoplantar pustulosis

Publications (2)

Publication Number Publication Date
JP2022515480A true JP2022515480A (ja) 2022-02-18
JP2022515480A5 JP2022515480A5 (enExample) 2022-12-21

Family

ID=69190739

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537716A Pending JP2022515480A (ja) 2018-12-27 2019-12-20 掌蹠膿疱症の処置のための抗ｉｌ－３６ｒ抗体

Country Status (14)

Country Link
US (3) US20200207862A1 (enExample)
EP (1) EP3902604A1 (enExample)
JP (1) JP2022515480A (enExample)
KR (1) KR20210119407A (enExample)
CN (1) CN113301955A (enExample)
AU (1) AU2019416727A1 (enExample)
BR (1) BR112021010789A2 (enExample)
CA (2) CA3265173A1 (enExample)
CL (1) CL2021001685A1 (enExample)
IL (1) IL284259A (enExample)
MX (1) MX2021007807A (enExample)
PH (1) PH12021551540A1 (enExample)
TW (1) TW202037604A (enExample)
WO (1) WO2020136101A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10526410B2 (en) 2015-04-15 2020-01-07 Anaptysbio, Inc. Antibodies directed against interleukin 36 receptor (IL-36R)
AU2019236105B2 (en) 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US11730812B2 (en) 2019-03-08 2023-08-22 Boehringer Ingelheim International Gmbh Anti-IL-36R antibody formulations
MX2023000763A (es) * 2020-07-17 2023-02-13 Boehringer Ingelheim Int Anticuerpos anti-il-36r para el tratamiento de dermatosis neutrofilas.
AU2021353854A1 (en) * 2020-09-30 2023-05-04 Boehringer Ingelheim International Gmbh Anti-il-36r antibodies for treatment of chronic inflammatory pain
CN112094349B (zh) * 2020-11-04 2021-02-09 上海华奥泰生物药业股份有限公司 靶向于白介素36r的抗体及其制备方法和应用
BR112023014103A2 (pt) * 2021-03-04 2023-10-10 Boehringer Ingelheim Int Métodos para o tratamento de gpp
EP4305207A2 (en) 2021-03-12 2024-01-17 Boehringer Ingelheim International GmbH Biomarkers associated with anti-il-36r antibody treatment in generalized pustular psoriasis
MX2023012903A (es) * 2021-05-03 2023-11-08 Boehringer Ingelheim Int Metodo para producir spesolimab.
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
WO2023285362A1 (en) * 2021-07-12 2023-01-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of il-36 inhibitors for the treatment of netherton syndrome
EP4638492A2 (en) * 2022-12-23 2025-10-29 Icosavax, Inc. Antibodies against metapneumovirus fusion (f) protein and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500633A (ja) * 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体
JP2017114829A (ja) * 2015-12-25 2017-06-29 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬
JP2018512157A (ja) * 2015-04-15 2018-05-17 アナプティスバイオ インコーポレイティッド インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO2009040602A1 (en) 2007-09-25 2009-04-02 Becton Dickinson France Autoinject0r with deactivating means moveable by a safety shield
CH705992A2 (de) 2012-10-11 2013-06-14 Tecpharma Licensing Ag Injektionsvorrichtung.
US11690956B2 (en) 2015-04-24 2023-07-04 Shl Medical Ag Sub-assembly of a medicament delivery device and a medicament delivery device
CH711066A2 (de) 2015-05-13 2016-11-15 Tecpharma Licensing Ag Verbesserte Injektionsvorrichtung.
AU2019236105B2 (en) * 2018-03-14 2025-07-31 Boehringer Ingelheim International Gmbh Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015500633A (ja) * 2011-11-16 2015-01-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ｉｌ−３６ｒ抗体
JP2018512157A (ja) * 2015-04-15 2018-05-17 アナプティスバイオ インコーポレイティッド インターロイキン３６受容体（ｉｌ−３６ｒ）に対する抗体
JP2017114829A (ja) * 2015-12-25 2017-06-29 国立大学法人名古屋大学 インターロイキン３６受容体アンタゴニスト欠損症の治療薬

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICALTRIALS.GOV ARCHIVE NCT03135548 ON 2018_11_15, JPN6023046828, 15 November 2018 (2018-11-15), ISSN: 0005322654 *
CLINICALTRIALS.GOV ARCHIVE NCT03633396 ON 2018_08_13, JPN6023046830, 13 August 2018 (2018-08-13), ISSN: 0005322656 *
THER. ADV. MUSCULOSKEL. DIS., vol. 9(11), JPN6023046829, 2017, pages 277 - 294, ISSN: 0005322655 *

Also Published As

Publication number Publication date
EP3902604A1 (en) 2021-11-03
US20200207862A1 (en) 2020-07-02
US20230115617A1 (en) 2023-04-13
CA3265173A1 (en) 2025-10-31
KR20210119407A (ko) 2021-10-05
CN113301955A (zh) 2021-08-24
MX2021007807A (es) 2021-08-11
BR112021010789A2 (pt) 2021-08-31
CL2021001685A1 (es) 2022-02-18
US20230131364A1 (en) 2023-04-27
PH12021551540A1 (en) 2022-02-21
AU2019416727A1 (en) 2021-07-22
TW202037604A (zh) 2020-10-16
CA3124996A1 (en) 2020-07-02
WO2020136101A1 (en) 2020-07-02
IL284259A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
US12503512B2 (en) Use of anti-IL-36R antibodies for treatment of generalized pustular psoriasis
US20230115617A1 (en) Anti-il-36r antibodies for treatment of palmoplantar pustulosis
US20230346926A1 (en) Methods of treating ankylosing spondylitis using il-17 antagonists
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
JP7662804B2 (ja) 汎発性膿疱性乾癬を処置する方法
US20220010022A1 (en) Anti-il-36r antibodies for the treatment of atopic dermatitis
US20160244520A1 (en) Compositions and methods for treating psoriatic arthritis
US20160002326A1 (en) Compositions and methods for treating rheumatoid arthritis
RU2845158C1 (ru) Способы лечения атопического дерматита путем введения антагониста il-4r
AU2014259523B2 (en) Methods of treating psoriatic arthritis using IL-17 antagonists
EA046186B1 (ru) Применение антител к il-36r для лечения генерализованного пустулёзного псориаза
HK1229257B (en) Methods of treating ankylosing spondylitis using anti-il-17 antibodies

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221213

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231114

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240201

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240514